Skip to content
Screener

Cytek Biosciences, Inc. CTKB Q3 2025 earnings

Reported November 5, 2025 · After market close

Revenue$52.3MMiss by $6.5M
EPS-$0.01Miss by $0.02
Revenue estimate$58.8M
EPS estimate$0.01

Next report

Nov 4, 2026 (in a month)
Revenue estimate$52.9M
EPS estimate-$0.07

Financials

Q3 2025

Income statement

See full
Revenue$52.3M+1.5%
Gross profit$27.6M-5.0%
Operating income-$9.2M-116%
Net income-$5.5M-682%
EPS (diluted)-$0.04-500%

Balance sheet

See full
Cash & equivalents$93.3M-42.5%
Total debt$17.2M+37.7%
Total equity$378.6M-1.8%
Total assets$494.9M+0.8%

Cash flow

See full
Operating cash flow-$3.9M-129%
CapEx$657.0K-35.0%
Free cash flow-$4.6M-137%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$441.47M-39.4%
Enterprise value$365.43M-36.8%
P/S2.2×-1.4×

Profitability

See full
Gross margin53.5%-1.5pp
FCF margin-3%-17.3pp

Returns & leverage

See full
Debt / equity0×0.0×
Current ratio5.2×-1.0×

Segments

By geography

See full
EMEA$12.4M-28.1%
APAC$11.1M+24.7%
Other$1.6M+59.8%

By segment

See full
Reportable Segment$52.3M+1.5%

By product

See full
Service$14.2M+18.6%

FAQ

When did Cytek Biosciences, Inc. report Q3 2025 earnings?
Cytek Biosciences, Inc. (CTKB) reported Q3 2025 earnings on November 5, 2025 after market close.
What were Cytek Biosciences, Inc.'s Q3 2025 revenue and EPS?
Cytek Biosciences, Inc. reported revenue of $52.3M and eps of $-0.01 for Q3 2025.
Did Cytek Biosciences, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $58.8M by $6.5M. EPS missed the consensus estimate of $0.01 by $0.02.
How did Cytek Biosciences, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 1.5% from $51.5M a year earlier.
Where can I find Cytek Biosciences, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-266973) and the 10-Q periodic report (0001628280-25-049697) directly on SEC EDGAR. The filing index links above go to sec.gov.